As we gear up for October’s World Vaccine Congress in Europe, we are delighted to see our start-up zone growing with new and familiar names. Read on to hear about some of the companies joining us, and to learn about the opportunities you could secure by adding your name to the list.  

Why be a start-up at the World Vaccine Congress? 

Start-ups whose applications are successful are entitled to several unique benefits, including exhibition wall space, 2 complimentary passes, and marketing materials. For the first time at this event, there is the opportunity to participate in a 5-minute pitch during lunch breaks, an exciting way of introducing yourselves to colleagues and potential partners.  

Our wonderful start-up manager, Isabella Aung, will receive your application and guide you through the process. She is looking forward to hearing more from interested companies, so do get in touch with her here via email (isabella.aung@terrapinn.comor head straight to the application page here 

“I am super excited to connect with and welcome even more start-ups to our start-up zone at our Congress this October! It’s going to be our biggest and most exciting start-up zone yet!”

This week we are pleased to introduce a further four start-ups who have already secured their spot in the start-up zone. To see the full list and find out more click here 

  • A biotech AI company helping pharmaceutical companies design vaccines and immunotherapies.
  • Modelling MHC binding to peptides and using generative AI to generate candidates of the antigens.
  • The team’s previous project was recognised by the Polish Health Ministry and deployed in a programme where the software processed over 50% of Polish PCR test results.
  • Over the past 18 months the team has been refining its technology and assembling a group of 12 scientists, AI engineers, and PhDs.
Global Malaria Vaccines GmbH (GMV)
  • A Berlin-based biotechnology company focused on malaria control and ultimate eradication through vaccination.
  • The company is solving the challenges of large-scale and low-cost industrialisation of new malaria vaccines and targeting both major species.
  • With a particular focus on vaccines that will aid elimination and eradication campaigns, GMV seeks to accelerate the development of new vaccines.
  • Staff have experience in the management and conduct of vaccine development projects and undertake horizon scanning for early awareness and potential access to new technologies, help partners with commercialisation opportunities, and help develop business cases for new investment.
  • The team’s strengths lie in technology transfer and vaccine development. GMV supports vaccine candidates through preclinical, CMC, clinical, and regulatory challenges. It also provides freedom-to-operate analyses and surveillance of the IP landscape surrounding key technologies.
  • An established not-for-profit organisation that is dedicated to improving global vaccination rates with a mission statement of “taking our best shot at immunising the world”.
  • Works globally to raise awareness of vaccine-preventable diseases and support the implementation of vaccination programmes.
  • The organisation has strong relationships within Canada and has delivered educational programmes, with a strong track record of digital content creation and delivery.
  • Ideally situated to address healthcare provider learning needs, with a team of healthcare professionals and dedicated technology experts who continue to reinvent educational programme delivery methods in line with learners’ evolving needs.
  • With practical experiences from immunisation providers and the power of technology, the organisation strives to improve vaccine accessibility and confidence across the world.
  • The team believes that the benefit of vaccinations is realised once they are administered to at-risk populations, so the focus is on the delivery of vaccinations and innovative implementation strategies to support community vaccination uptake.
Pegasus Biotech Inc.
  • A Contract Research Organisation focused on biopharmaceuticals and DNA vaccines for human and animal health markets.
  • The mission is to work with clients to bring cutting-edge innovation to the global human and animal health markets.
  • The team’s area of expertise is ensuring that CMC development activities for client projects (process and analytical development), in the proof-of-concept stage or moving into production, result in commercially viable products that are compliant with global regulations.

If you would like to join your colleagues in this exciting and continuously growing start-up zone, fill out an application here or contact Isabella here: 

Stay tuned for more start-up news, and make sure you subscribe to our weekly newsletters!